English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Alzheimer’s disease (AD) is a severe neurodegenerative disorder still in search of effective methods of diagnosis. Altered levels of the NMDA receptor co-agonist, D-serine, have been associated with neurological disorders, including schizophrenia and epilepsy. However, whether D-serine levels are deregulated in AD remains elusive. Here, we first measured D-serine levels in post-mortem hippocampal and cortical samples from nondemented subjects (n = 8) and AD patients (n = 14). We next determined D-serine levels in experimental models of AD, including wild-type rats and mice that received intracerebroventricular injections of amyloid-β oligomers, and APP/PS1 transgenic mice. Finally, we assessed D-serine levels in the cerebrospinal fluid (CSF) of 21 patients with a diagnosis of probable AD, as compared with patients with normal pressure hydrocephalus (n = 9), major depression (n = 9) and healthy controls (n = 10), and results were contrasted with CSF amyloid-β/tau AD biomarkers. D-serine levels were higher in the hippocampus and parietal cortex of AD patients than in control subjects. Levels of both D-serine and serine racemase, the enzyme responsible for D-serine production, were elevated in experimental models of AD. Significantly, D-serine levels were higher in the CSF of probable AD patients than in non-cognitively impaired subject groups. Combining D-serine levels to the amyloid/tau index remarkably increased the sensitivity and specificity of diagnosis of probable AD in our cohort. Our results show that increased brain and CSF D-serine levels are associated with AD. CSF D-serine levels discriminated between nondemented and AD patients in our cohort and might constitute a novel candidate biomarker for early AD diagnosis. Translational Psychiatry (2015) 5, e561; doi:10.1038/tp.2015.52; published online 5 May 201

d-serine levels in Alzheimer’s disease: implications for novel biomarker development